165 related articles for article (PubMed ID: 8853479)
1. Prostate cancer: the epidemiologic perspective.
Levy I
Can J Oncol; 1994 Nov; 4 Suppl 1():4-7. PubMed ID: 8853479
[No Abstract] [Full Text] [Related]
2. [Prostate cancer: view of the horizon].
Dauriac P
Rev Infirm; 2004 Mar; (99):18-9. PubMed ID: 15124488
[No Abstract] [Full Text] [Related]
3. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
4. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
5. Young men with prostate cancer: are they different and how should they be managed?
Khan MA
BJU Int; 2007 May; 99(5):1169. PubMed ID: 17437448
[No Abstract] [Full Text] [Related]
6. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
[TBL] [Abstract][Full Text] [Related]
7. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series.
Walz J; Graefen M; Chun FK; Erbersdobler A; Haese A; Steuber T; Schlomm T; Huland H; Karakiewicz PI
Eur Urol; 2006 Sep; 50(3):498-505. PubMed ID: 16631303
[TBL] [Abstract][Full Text] [Related]
8. [Cancer of the prostate. Diagnosis, prognosis, principles of treatment].
Lopez JG; Perrin P
Rev Prat; 1999 Feb; 49(3):297-301. PubMed ID: 10189800
[No Abstract] [Full Text] [Related]
9. [Incidence and epidemiology of prostatic cancer in the Urology Department at CHU-Tokoin (Lome-Togo)].
Anoukoum T; Attipou KK; Napo-Kaoura AG; Ayite A; Safwat Y; James K
Tunis Med; 1998 Feb; 76(2):1061-4. PubMed ID: 9844543
[No Abstract] [Full Text] [Related]
10. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups.
Sandblom G; Holmberg L; Damber JE; Hugosson J; Johansson JE; Lundgren R; Mattsson E; Nilsson J; Varenhorst E
Scand J Urol Nephrol; 2002; 36(2):106-12. PubMed ID: 12028683
[TBL] [Abstract][Full Text] [Related]
11. Update on the diagnosis and management of prostate cancer.
LaSpina M; Haas GP
Can J Urol; 2008 Aug; 15 Suppl 1():3-13; discussion 13. PubMed ID: 18700060
[TBL] [Abstract][Full Text] [Related]
12. Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.
CMAJ; 1991 Sep; 145(5):413-28. PubMed ID: 1878824
[No Abstract] [Full Text] [Related]
13. Prostate cancer--the snowball is rolling.
Ruutu M; Salo J; Nordling S; Rannikko S
Ann Chir Gynaecol; 1999; 88(1):5-8. PubMed ID: 10230675
[No Abstract] [Full Text] [Related]
14. [Treatment of clinically localized prostate cancer. Part I--observation or treatment?].
Szelachowska J; Kornafel J; Gisterek I
Pol Merkur Lekarski; 2006 Dec; 21(126):594-7. PubMed ID: 17405305
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association.
Cancer Registration Committee of the Japanese Urological Association
Int J Urol; 2005 Jan; 12(1):46-61. PubMed ID: 15661054
[TBL] [Abstract][Full Text] [Related]
16. The long-awaited drop in prostate cancer mortality: what does it mean?
Levy IG
Cancer Prev Control; 1998 Aug; 2(4):159. PubMed ID: 10093626
[No Abstract] [Full Text] [Related]
17. [Screening for prostatic cancer].
Pushkar' DIu; Govorov AV; Bormotin AV
Urologiia; 2003; (1):10-5. PubMed ID: 12621959
[TBL] [Abstract][Full Text] [Related]
18. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
20. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
Porter MP; Stanford JL; Lange PH
Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
